First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

An overlooked immune cell population may offer new direction for cell and gene therapy

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

Cancer Policy

Supreme Court lifts lower-court freeze on RIFs

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

HHS asks employees to report instances of “DEI policies that caused discrimination”

Medical, cancer groups respond to Trump’s “Big Beautiful Bill” becoming law

Congress passes Trump’s megabill featuring historically steep Medicaid cuts

Clinical Roundup

Subtle challenges to women’s authority increases burnout among surgeons, survey data shows

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Weight-associated breast cancer risk is higher in women with cardiovascular disease, IARC analysis shows

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

In The Clinic

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Latest Issue

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

Sep 2025

Oct 2025

Conversations with The Cancer Letter

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Contributors

George J. Weiner, MD

Alan H. Bryce, MD

Nataliya Kovalchuk, PhD

Donald L. "Skip" Trump, MD

First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

An overlooked immune cell population may offer new direction for cell and gene therapy

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

Supreme Court lifts lower-court freeze on RIFs

House Dems host “The Things We’ll Never Know: A Science Fair of Canceled Grants”

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

HHS asks employees to report instances of “DEI policies that caused discrimination”

Medical, cancer groups respond to Trump’s “Big Beautiful Bill” becoming law

Congress passes Trump’s megabill featuring historically steep Medicaid cuts

Subtle challenges to women’s authority increases burnout among surgeons, survey data shows

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Weight-associated breast cancer risk is higher in women with cardiovascular disease, IARC analysis shows

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

CRC patients with cannabis use disorder may have higher odds of death within five years of diagnosis
Observational study suggests that clinicians should be cautious when recommending cannabis to manage cancer symptoms

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

George J. Weiner, MD

Alan H. Bryce, MD

Nataliya Kovalchuk, PhD

Donald L. "Skip" Trump, MD

Never miss an issue!

Login

First-ever financial toxicity tumor board aims to change the standard of careResearchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Never miss an issue!

Login

First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI